A Case of Successful Immunosuppressive Therapy for Interstitial Lung Disease Associated with Sjögren's Syndrome With Double-positive Anti-SS-A and Anti-centromere Antibodies-Reference-Cited by-同舟云学术

A Case of Successful Immunosuppressive Therapy for Interstitial Lung Disease Associated with Sjögren's Syndrome With Double-positive Anti-SS-A and Anti-centromere Antibodies

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Suzuki Koji¹,Akiyama Mitsuhiro¹,Kondo Yasushi¹,Saito Shuntaro¹,Kikuchi Jun¹,Hanaoka Hironari¹,Kaneko Yuko¹

Affiliation:

1. Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_3384-23/_pdf

Reference15 articles.

1. 1. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, et al. 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol 69: 35-45, 2017.

2. 2. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol 2012: 606195, 2012.

3. 3. Tsukamoto M, Suzuki K, Takeuchi T. Clinical and Immunological Features of Anti-centromere Antibody-Positive Primary Sjögren's Syndrome. Rheumatol Ther 5: 499-505, 2018.

4. 4. Suzuki Y, Fujii H, Nomura H, Mizushima I, Yamada K, Yamagishi M, et al. Impact of double positive for anti-centromere and anti-SS-a/Ro antibodies on clinicopathological characteristics of primary Sjögren's syndrome: a retrospective cohort study. Mod Rheumatol 28: 872-878, 2018.

5. 5. Gupta S, Ferrada MA, Hasni SA. Pulmonary manifestations of primary sjögren's syndrome: Underlying immunological mechanisms, clinical presentation, and management. Front Immunol 10: 2019.